Hologic (NSDQ:HOLX) said today it launched its Brevera breast biopsy system designed for real-time breast biopsy and verification.
The Marlborough company’s Brevera system features CorLumina imaging technology to streamline the biopsy process and enhance workflow, the company said. The device is intended to increase biopsy accuracy and deliver results at the point of care for more informed decision making.
Hologic touted the Brevera system as the world’s 1st and only such system to combine tissue acquisition, real-time imaging, sample verification and post-biopsy handling in a single device. The system is designed for both 2D and 3D breast biopsies, the company said.
“We’re proud to launch the Brevera system, a major breakthrough for radiologists who, for the 1st time, will be able to image and verify tissue samples in real-time in the procedure room. The Brevera system provides clinicians with more information at the point of care and women with a vastly improved experience, resulting in significant cost and time savings without compromising accuracy or patient health outcomes. The system transforms the stereotactic breast biopsy procedure as we know it, and serves as further proof of Hologic’s commitment to better serve the needs of our customers and their patients,” Hologic breast and skeletal health division prez Pete Valenti said in a press release.
The Brevera system is designed for use with Hologic’s Affirm prone biopsy system, Affirm breast biopsy guidance system and MultiCare platinum system, the company said.
In June, Hologic said it won new FDA labeling for its Genius 3D mammography system, touting it as the only such device approved as superior to 2D mammography in women with dense breasts.